A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma | MicrobiomeTrials← Back to trialsNCT04045470
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2019-12-11Est. Completion: 2027-07-31
Enrollment target: 20 participants Locations- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Cutaneous T-Cell Lymphoma/Mycosis FungoidesPrimary Cutaneous Anaplastic Large Cell Lymphoma
This is a prospective, single-center, open-label, randomized, controlled phase II clinical trial. The main purpose of th…
Beijing, ChinaEst. completion Dec 30, 2028
T-Cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Peripheral T Cell Lymphoma
Anaplastic Large Cell Lymphoma
Adult T Cell Leukemia
Adult T Cell Lymphoma
T Cell Prolymphocytic Leukemia
Extranodal NK/T-cell Lymphoma
Transformed Mycosis Fungoides
Sezary Syndrome
Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL)…
St Louis, United StatesCompleted Jun 30, 2027